Cytotoxic properties of clofibrate and other peroxisome proliferators: relevance to cancer progression. 2010

F Penna, and G Bonelli, and F M Baccino, and P Costelli
Department of Experimental, Medicine and Oncology, University of Torino, Corso Raffaello 30, Turin, Italy.

The biological activity of peroxisome proliferators (PPs) is mediated by a class of receptors, known as PPARs (PP-Activated Receptor), belonging to the nuclear receptor superfamily. Upon ligand binding, PPARs dimerize with retinoid receptors, translocate to the nucleus, recognize specific PP-responsive elements on DNA and transactivate a number of genes. Several processes are regulated by PPARs, such as mitochondrial and peroxisomal fatty acid uptake and beta-oxidation, inflammation, intracellular lipid trafficking, cell proliferation and death. In addition, PPARs have been proposed to act as tumor suppressors or as tumor promoters, depending on the circumstances. In particular, PPs have been extensively studied for their hepatocarcinogenic action in rodents, most often ascribed to their antiapoptotic action. Recent evidence, however, has been provided about the antiproliferative, proapoptotic, and differentiation-promoting activities displayed by PPAR ligands. The present review will focus on the cytotoxic effects exerted by several PPs, among which clofibrate, on different types of tumor cells, with particular reference to the mechanisms of cell death and to their relevance to cancer induction and progression.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002994 Clofibrate A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986) Athromidin,Atromid,Atromid S,Clofibric Acid, Ethyl Ester,Ethyl Chlorophenoxyisobutyrate,Miscleron,Miskleron,Chlorophenoxyisobutyrate, Ethyl
D003603 Cytotoxins Substances that are toxic to cells; they may be involved in immunity or may be contained in venoms. These are distinguished from CYTOSTATIC AGENTS in degree of effect. Some of them are used as CYTOTOXIC ANTIBIOTICS. The mechanism of action of many of these are as ALKYLATING AGENTS or MITOSIS MODULATORS. Cytolysins,Cytotoxic Agent,Cytotoxic Agents,Cytotoxin,Agent, Cytotoxic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D047492 Peroxisome Proliferator-Activated Receptors TRANSCRIPTION FACTORS that are activated by ligands and heterodimerize with RETINOID X RECEPTORS and bind to peroxisome proliferator response elements in the promoter regions of target genes. Peroxisome Proliferator-Activated Receptor,NUC1 PPAR,PPAR,PPAR, NUC1,Peroxisome Proliferator Activated Receptor,Peroxisome Proliferator Activated Receptors,Proliferator-Activated Receptor, Peroxisome,Proliferator-Activated Receptors, Peroxisome,Receptor, Peroxisome Proliferator-Activated,Receptors, Peroxisome Proliferator-Activated
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease
D020025 Peroxisome Proliferators A class of nongenotoxic CARCINOGENS that induce the production of hepatic PEROXISOMES and induce hepatic neoplasms after long-term administration. Proliferators, Peroxisome

Related Publications

F Penna, and G Bonelli, and F M Baccino, and P Costelli
May 2004, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews,
F Penna, and G Bonelli, and F M Baccino, and P Costelli
August 2003, Journal of biochemistry,
F Penna, and G Bonelli, and F M Baccino, and P Costelli
August 1995, Seikagaku. The Journal of Japanese Biochemical Society,
F Penna, and G Bonelli, and F M Baccino, and P Costelli
April 1995, Xenobiotica; the fate of foreign compounds in biological systems,
F Penna, and G Bonelli, and F M Baccino, and P Costelli
December 1996, Annals of the New York Academy of Sciences,
F Penna, and G Bonelli, and F M Baccino, and P Costelli
January 1993, Biochimie,
F Penna, and G Bonelli, and F M Baccino, and P Costelli
May 1993, Toxicology letters,
F Penna, and G Bonelli, and F M Baccino, and P Costelli
December 1996, Annals of the New York Academy of Sciences,
F Penna, and G Bonelli, and F M Baccino, and P Costelli
January 1994, European journal of drug metabolism and pharmacokinetics,
Copied contents to your clipboard!